

How to deposit iPSC lines into EBiSC

1




Initial Depositor Application

Apply to deposit your iPSC line(s)

www.EBiSC.org/depositors/



2



Consent Review

Provide copies of the Consent Form
and Participant Information Sheet
templates used to collect Biosamples



3



Cell Line Data Capture

Share information on the donor and
iPSC lines using the hPSCreg data portal
(<https://hpscereg.eu/>)



4



Formalise Deposition

Complete the EBiSC Material Deposit
Agreement (EMDA)



5



iPSCs listed at
www.EBiSC.org/search!

European Bank for induced Pluripotent Stem Cells



The **European Bank for induced Pluripotent Stem Cells** (EBiSC) is a not-for-profit iPSC repository, enabling academic and commercial researchers to access quality-assured, disease relevant, research-grade iPSC lines, data and cell services.

How EBiSC can help accelerate your research*:

- EBiSC can advise on how to establish a **legal and ethical framework** for your iPSC research programme and perform **iPSC services** such as **reprogramming, gene-editing, differentiation** and **QC** upon request.
- EBiSC will share all **characterisation data** on your iPSC lines with you.
- **Avoid future costs** associated with maintenance and distribution of your iPSCs.
- **Reduce time** spent negotiating multiple MTAs with others to share your lines for collaboration.
- Be acknowledged as the **owner of your iPSC lines**.
- Enhance the chance of **commercial out-licensing** (at your decision).
- Satisfy the requirements of **funding bodies and journals** to share iPSC lines after publication.
- Avoid potential loss of precious material as EBiSC acts as a **safe backup** repository for your iPSC lines.
- Receive a **two-vial credit** for each cell line banked with EBiSC, to be used for obtaining vials of cell lines deposited by yourself or others in EBiSC.

Want to find out more?

Please see our **website** for further information:
www.EBiSC.org/depositors/

Please also feel free to directly contact the
EBiSC BioSample Acquisition Team: **Contact@EBiSC.org**



* Subject to terms. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821362. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA

